Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Tartisan Nickel Plans Initial 5,000 Meters of Phase 2 Drilling in Northwestern Ontario

Tartisan Nickel Plans Initial 5,000 Meters of Phase 2 Drilling in Northwestern Ontario

MT newswireMT newswire2026/11/03 14:46
10:46 AM EST, 11/03/2026 (MT Newswires) -- Tartisan Nickel (TN.CN) proposed a Phase 2 diamond drilling program at its Kenbridge Nickel-Copper-Cobalt project near Sioux Narrows, in the Kenora Mining District of Northwestern Ontario, it said in a statement on Tuesday. The company said the program initially contemplates about 5,000 meters of drilling to expand the existing mineral resource estimate by testing the down-dip continuation of the deposit and a modelled borehole electromagnetic (BHEM) plate 209. The proposed Phase 2 program comprises initially four diamond drill holes, it said. Shares of the company were last seen up 7.7% at CA$0.07 on the Canadian Securities Exchange. Price: 0.07, Change: +0.01, Percent Change: +7.69
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss